Alpine Immune Sciences (AIS) was founded in 2015 and seed funded by Alpine BioVentures. AIS is focused on developing novel protein�based immunotherapies using its proprietary variant immunoglobulin domain (vIgD™) platform technology. The vIgD™ platform, unlike other therapeutic approaches in development or available commercially, is designed to interact with multiple targets simultaneously in the immune synapse using a single molecule. AIS' vIgDs™ are developed using a unique process known as directed evolution to leverage the naturally occurring ligands immune cells use to communicate. AIS has developed its vIgD™ platform to either enhance or diminish an immune response, making the vIgD™ technology applicable for both cancer indications as well as for autoimmune diseases. AIS has also developed its transmembrane immunomodulatory protein (TIP™) technology, based on the vIgD™ platform, for direct applications with engineered cellular therapies, potentially improving their efficacy and persistence. In October of 2015 AIS signed a worldwide research and license agreement with Kite Pharma, Inc. worth up to $530 million allowing Kite access to certain targets developed using the AIS TIP„¢ platform.

Key Contact